Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + tezatinib
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel + tezatinib is a combination of two investigational or approved anticancer agents. Paclitaxel is a well-established chemotherapeutic agent from the taxane class that works by stabilizing microtubules and inhibiting their disassembly during cell division. This disrupts mitosis and leads to cancer cell death[2][6][8]. Tezatinib is presumed to be a small molecule inhibitor targeting specific kinases involved in cancer progression; however, there are no publicly available clinical or preclinical data confirming its mechanism of action or development status as of June 2025. The combination would theoretically leverage the cytotoxic effects of paclitaxel with targeted inhibition by tezatinib for enhanced antitumor activity.
- Brand names
- Taxol
- Other names
- nab-paclitaxelalbumin-bound paclitaxelABI-007ABI007ABI 007BMS 181339-01BMS181339-01BMS-181339-01DHP 107DHP107DHP-107MBT 0206MBT0206MBT-0206NK 105NK105NK-105
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + tezatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + tezatinib.